JWJinfeng Wen

Jinfeng Wen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinfeng Wen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Cuiyan Wu

    School of Public Health, Health Science Center Xi'an Jiaotong University, Key Laboratory of Environmental and Endemic Diseases of National Health Commission of the People's Republic of China Xi'an Shaanxi China

    1 shared publication
  • Cuiyan Wu

    School of Public Health, Health Science Center, Xi'an Jiaotong University, Key Laboratory of Environmental and Endemic Diseases of National Health Commission of the People's Republic of China, Xi'an 710061, Shaanxi, PR China

    1 shared publication
  • Feng Zhang

    School of Public Health, Health Science Center Xi'an Jiaotong University, Key Laboratory of Environmental and Endemic Diseases of National Health Commission of the People's Republic of China Xi'an Shaanxi China

    1 shared publication
  • Gaowa Naren

    School of Public Health, Health Science Center Xi'an Jiaotong University, Key Laboratory of Environmental and Endemic Diseases of National Health Commission of the People's Republic of China Xi'an Shaanxi China

    1 shared publication
  • Huan Liu

    School of Public Health, Health Science Center Xi'an Jiaotong University, Key Laboratory of Environmental and Endemic Diseases of National Health Commission of the People's Republic of China Xi'an Shaanxi China

    1 shared publication
  • Huan Liu

    Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, China

    1 shared publication

Latest Publications

  • Transcriptomic and Metabolomic Mechanism of Ibuprofen, Chondroitin Sulfate, and Vitamins With Minerals Tablets (21) for Kashin–Beck Disease Treatment

    by Jinfeng Wen, Xingxing Deng, Zhengjun Yang, Hui Niu, Qian Zhang, Yijun Zhao, Gaowa Naren, Huan Liu, Feng Zhang, Xiaodong Yang, et al.

    Background: Kashin–Beck disease (KBD) is an osteoarthropathy with no specific drug treatment. This study seeks to uncover the molecular mechanisms of ibuprofen, chondroitin sulfate, and vitamins with minerals tablets (21) in treating KBD. Methods: Integrated transcriptomic and metabolomic analyses were performed on peripheral blood samples collected from four KBD patients before and 1 month after treatment. Differential gene expression was assessed using the DESeq package, while differential metabolites were identified through univariate and multivariate statistical analyses. Results: After treatment, 5671 differential genes (|log 2 FC| ≥ 1, q < 0.05) were identified, with 4954 upregulated and 717 downregulated. Enriched pathways included PI3K‐Akt, MAPK, ECM‐receptor interaction, Rap1, and Ras signaling. Untargeted metabolomics analyses revealed five differentially expressed metabolites (VIP ≥ 1, |log 2 FC| > 0.58, p < 0.05): L‐glutamine, 2‐methylpropan‐2‐amine, epsilon‐caprolactam, phosphocholine, and 1‐palmitoyl‐2‐linoleoyl‐sn‐glycero‐3‐phosphocholine. Metabolite enrichment analysis suggested alterations in amino acid and fatty acid metabolism. Integrated analysis revealed key pathways such as alanine, aspartate, and glutamate metabolism and arginine biosynthesis. Conclusions: The combination of ibuprofen, chondroitin sulfate, and vitamins with minerals tablets (21) may alleviate KBD through modulation of key genes (GDNF, BDNF, CCL2, VEGFA, and PPARG) and glutamine‐related metabolic pathways.


  • Open Access

    Identification and Verification of Hub Mitochondrial Dysfunction Genes in Osteoarthritis Based on Bioinformatics Analysis

    by Hui Niu, Xingxing Deng, Qian Zhang, Yijun Zhao, Jinfeng Wen, Wenyu Li, Huan Liu, Xiong Guo, Cuiyan Wu

    Objective. Age‐related mitochondrial dysfunction and associated oxidative stress may contribute to the development of osteoarthritis. The aim of this study was to identify hub genes associated with mitochondrial dysfunction in osteoarthritis (OA) patients, helping predict the risk of OA, and revealing the mechanism of OA progression. Methods. OA expression data and mitochondrial dysfunction genes were downloaded from GEO (GSE55235, GSE82107, and GSE114007) and GeneCard databases. The differentially expressed mitochondrial dysfunction genes (DEMDFGs) between OA and control samples were screened. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes pathways were analyzed for DEMDFGs. The hub genes were determined by WGCNA and LASSO regression analysis. ROC curves manifested the diagnostic efficacy of each hub gene. A nomogram model was constructed and validated to predict OA risk. The expression of hub genes in OA and normal chondrocytes was verified by external datasets, qRT‐PCR and western blotting. Results. A total of 31 DEMDFGs were identified, with 15 genes upregulated and 16 genes downregulated. GO functional enrichment analysis revealed that DEMDFGs were enriched in biological processes related to energy metabolism and cellular respiration. By employing weighted gene coexpression network analysis, we identified four distinct coexpression modules, among which the blue module exhibited the strongest correlation with OA. The intersection between DEMDFGs and this module yielded eight candidate genes. After LASSO analysis of the data, four hub genes (ACADL, CYBA, SLC19A2, and UCP2) were identified as potential biomarkers for OA. The expression levels of these four genes were externally validated in the GSE114007 dataset. And the biologically differential expression of these four genes has been verified in OA and normal chondrocytes. Moreover, the four hub genes had good sensitivity and specificity by ROC curve analysis, and the risk model constructed with these four genes showed promising performance. In conclusion, our study may provide novel mitochondrial dysfunction hub genes with potential clinical applications for understanding the pathology, diagnosis, and treatment of OA.